---
document_datetime: 2023-09-21 17:25:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_en.pdf
document_name: litak-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8092534
conversion_datetime: 2025-12-20 00:28:45.647537
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU numbers      | Invented name   | Strength   | Pharmaceutical Form    | Route of administration   | Packaging    | Content   | Package size   |
|-----------------|-----------------|------------|------------------------|---------------------------|--------------|-----------|----------------|
| EU/1/04/275/001 | Litak           | 2 mg/ml    | Solution for injection | Subcutaneous use          | Vial (glass) | 5ml       | 1 vial         |
| EU/1/04/275/002 | Litak           | 2 mg/ml    | Solution for injection | Subcutaneous use          | Vial (glass) | 5ml       | 5 vials        |